160 results about "Iothalamate Meglumine" patented technology

The invention discloses an aprepitant microemulsion for injection. The aprepitant microemulsion consists of the following components in percentage by mass: 0.05 to 2 percent of aprepitant, 5 to 30 percent of oil for injection, 0.5 to 10 percent of emulsifier, 1 to 10 percent of co-emulsifier, 5 to 20 percent of protective agent and 60 to 80 percent of water for injection. Compared with the conventional oral aprepitant, the aprepitant microemulsion for the injection has the outstanding advantage that: the aprepitant is insoluble in the water and an organic solvent, in order to realize the aprepitant injection, the aprepitant microemulsion and aprepitant micro emulsion freeze-drying powder are prepared successfully and can be subjected to large-scale industrial production; and compared with a fosaprepitant dimethyl-meglumine injection, the aprepitant microemulsion has the advantages that: the cost is reduced greatly, the practicality is extremely high, and economic and social benefits are relatively good.

The invention discloses a Lansoprazole preparation for injection comprising (1) Lansoprazole 10-50 weigh parts, (2) meglumine 2-20 weight parts, (3) sodium hydroxide 1-5 weight parts, (4) mannitol 20-100 weight parts. The invention also discloses the process for preparing the preparation.

The invention provides a freeze-dried powder of lansoprazole for injection and a preparation method of the freeze-dried powder which consists of lansoprazole, meglumine and mannitol with the weight ratio of 3:1:18 to 22. The invention provides the preparation method: dissolving raw and supplemental materials with water and adjusting the pH, and adding activated carbon to remove the color and filtering to remove the carbon; making fine filtration with a filtering film and loading separately and cooling rapidly to minus 50 to minus 46 DEG C with the speed of 1 to 1.2 DEG C per minute; preserving the heat and freezing for 3 hours and pumping the vacuum to 15Pa; heating uniformly to minus 22 to minus 18 DEG C in 7 to 9 hours and preserving the heat for 1 hour to 2 hours; heating rapidly to 3 to 7 DEG C in 4 to 6 hours and then heating to 40 DEG C in 4 hours; preserving the heat and drying for 3 hours and packaging and warehousing after the measuring there. Products prepared by the method are low in water content, beautiful in appearance and easy in storage and transportation.

The present invention relates to an adenosine cyclophosphate injection and a preparing process thereof. According to the invention, acidum citricum is added into a magnetic stirring pot. Injection water with confect amount of 50% is added and dissolved. The adenosine cyclophosphate and meglumine are added into the solution. The obtained solution is mixed to be dissolved. The 0.02% of activated carbon with needle use in volume is added. The mixture is mixed for 30 minutes. The mixture is preliminarily filtered fro removing carbon. The adenosine cyclophosphate injection is prepared for standby. The injection water is added to the total amount. The pH value is adjusted to 6.0-6.5 by sodium hydroxide solution with concentration of 10%. The colorless transparent injection is prepared. The adenosine cyclophosphate injection of the invention not only has the advantages of straight function, high speed, etc., but also has the advantages of little adverse effect, normal temperature transportation and normal preserving, thereby increasing the stability and safety of the product.

The present invention relates to one kind of orally disintegrated silibinin-meglumine salt tablet for protecting liver cell, stimulating the biological synthesis of protein inside liver cell, promoting recovery of damaged liver cell, resisting fibrillation, capturing free oxygen radical and inhibiting the deposition and infiltration of fat in liver, and its preparation. The orally disintegrated silibinin-meglumine salt tablet is prepared with silibinin-meglumine salt as main material, and through adding stuffing, disintegrating agent, corrective, flow assistant and other supplementary material, pressing into tablet and other steps. The present invention has the features of low production cost, fast disintegration, good taste, etc.

The garcinolic acid injection as one kind of Chinese medicine preparation contains garcinolic acid as active component as well as cosolvent, excipient, and water for injection. Its preparation process includes weighing material garcinolic acid in 1-50 weight portions, adding water for injection in 0-4000 weight portions via stirring, adding cosolvent in 1-50 in weight portions before ultrasonic dissolving, adding excipient 1-100 in weight portions through stirring to dissolve, adding active carbon during stirring, eliminating carbon, filtering and packing. The injection may be freeze dried to prepare freeze dried injection. The cosolvent is selected from L-arginine, meglumine and lysine; and the excipient is selected from mannitol, dextran and sodium chloride.

This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

The present invention relates an additive comprising at least one substance selected from arginine, trometamol, meglumine, lysine, histidine, monoethanolamine, diethanolamine, triethanolamine, succinic acid, citric acid, tartaric acid, lactic acid, and salts thereof, which is useful in the prevention of aggregation of fine particulate complexes of a nucleic acid and collagen, and the production of a preparation comprising particulate complexes of controlled size which is suited for transporting a nucleic acid into cells.

The invention relates to a preparation method of chemical medicine, in particular to meglumine adenosine cyclophosphate composition injection and a preparation method thereof. The meglumine adenosine cyclophosphate composition injection comprises the following ingredients in part by weight: 5 to 15 parts of adenosine cyclophosphate, 3 to 10 parts of meglumine, 2.0 to 2.2 parts of citric acid, 0.6 to 0.8 parts of sodium hydroxide, 2 to 4 parts of sodium chloride and 2 to 5 parts of water for injection. The preparation method comprises the following steps that the citric acid is mixed and dissolved in the water for injection, the pH value of the mixed solution is adjusted to 5.9 to 6.5 by the sodium hydroxide to form buffering solution, then the sodium chloride and latent solvent are added into the buffering solution to be stirred and dissolved, the water for injection is added, the adenosine cyclophosphate and meglumine are slowly added while the solution is stirred, active carbon is added and stirred in the solution after the adenosine cyclophosphate and the meglumine are completely dissolved, and the mixed solution is filtered and reflowed to prepare colorless clear and bright liquid. The clarity of the injection is good, the stability is good, and the injection is safe to use.

The invention discloses a prescription of a repaglinide-metformin hydrochloride tablet and a preparation technology thereof. In particular, a solid dispersion water solution technology is used; the problem that repaglinide is insoluble in water can be solved only through common wet granulations; dissolved objects and related matter are both superior to those of foreign objects. Microcrystalline celluloses and sorbitol serve as fillers; polyvinylpolypyrrolidone serves as disintegrating agents; PVPk30 serves as bonding agents; silicon dioxide serves as lubricating agents; meglumine serves as saltiness agents; and poloxamer 188 serves as solubilizers. The repaglinide-metformin hydrochloride tablet prepared with the technology is fewer in use auxiliary material; the high dissolving performance and the high stability can be kept; the preparation technology is simple; the technology cost is lower; and the repaglinide-metformin hydrochloride tablet is suitable for industrial production.

The water soluble silymarin preparation consists of silymarin, meglumine, PVP and poloxamer. It is prepared through dissolving silymarin and cosolvent in ethanol, filtering, reflux reaction and concentrating to obtain extractum; drying to obtain dry paste; redissolving, vacuum concentrating to crystallize, suction filtering to obtain crystal; ethanol washing, suction filtering, re-crystallizing and drying to obtain crystal; crushing, mixing and packing to obtain the water soluble silymarin preparation. The present invention features high water solubility, high stability and high bioavailability.